AzTrials
AzTrials

OligoasthenoteratozoospermiaPhase 2NCT05200663

Efficacy Comparison of Tamoxifen and Tamoxifen With Antioxidants on Semen Quality of Male With Idiopathic Infertility

A Phase 2 study testing Tab Tamoxifen 10 mg and Tab Tamoxifen 10mg,Cap vitamin E 400mg in people with Oligoasthenoteratozoospermia and Male Infertility, run by Sharif Medical Research Center at 1 site in Pakistan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Objective of the study is to compare the efficacy of tamoxifen alone \& tamoxifen with antioxidant on semen quality of infertile male with abnormal parameters (sperm count, motility, vitality, morphology) .Infertility is defines as inability to conceive after one year of unprotected and regular intercourse. Read more about this study

Who is it for?
Any age, men onlyHealthy volunteers can take part
What is being tested?
Tab Tamoxifen 10 mg and Tab Tamoxifen 10mg,Cap vitamin E 400mg
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
110 participants
Where
1 sitePakistan
Study dates
15 Oct 2021to Oct 2022
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Men only
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • All infertile male with idiopathic infertility and abnormal semen analysis.

Who cannot join

  • 1. Leukocytospermia i.e. significant WBCs seen in the semen, 2. Severe oligospermia (sperm count <5 million per ml),

Trial locations and contacts

1 site in 1 country.

Anees Fatima, MBBS,FCPS. contact

03456224197 ext. +92

fatima.tabjeel@gmail.com

Fauzia Butt, MBBS,FCPS, contact

03009427094

drfauziabutt@hotmail.com

Pakistan1 site, 1 recruiting
  • Sharif Medical And Dental College

    Lahore, Punjab Province, 54000

    Anees Fatima, MBBS,FCPS, 03456224197 ext. +92, fatima.tabjeel@gmail.com

    Recruiting

Other trials in Pakistan

About this study

Official title: Comparison of the Efficacy of the Tamoxifen and Tamoxifen With Antioxidants on Semen Quality of Infertile Male With Abnormal Semen Parameters.

Objective of the study is to compare the efficacy of tamoxifen alone \& tamoxifen with antioxidant on semen quality of infertile male with abnormal parameters (sperm count, motility, vitality, morphology) .Infertility is defines as inability to conceive after one year of unprotected and regular intercourse. Infertility is the most important issue in the married couples and is one of the major clinical problem affecting people medically and psychologically .It affects about 5.8 to 44.2 % couples in the developing countries. Male infertility contributes to about 50% of the overall infertility. Antiestrogens are considered as one of the old and most commonly prescribed treatment of idiopathic infertility.Many studies has shown that it improves idiopathic oligozoospermia, count, motility and vitality. Spermatozoa are also prone to oxidative damage.

Men who have high reactive oxygen species(ROS) may have lower fertility potential as compared to men with low ROS. High levels of ROS in semen have been correlated with reduced sperm motility and damage to sperm nuclear DNA. High levels of cytokines in the semen is correlated with sperm injury like cell membrane lipid peroxidation in the presence of raised IL-6 .Antioxidents are the most important form of protection for spermatozoa against ROS. So oral antioxidents are commonly prescribed to males with idiopathic abnormal semen parameters and infertility to reduce the oxidative stress and improves infertility.

It is a single blinded randomized control trial to be conducted in Sharif Medical and Dental college, Lahore with sampling technique of probability randomized consecutive sampling technique. 110 male patients with idiopathic male infertility and abnormal semen parameters will be recruited . Pre treatment semen analysis and LH, FSH and serum testosterone will be done. 55 patients will be given tamoxifen alone ad 55 patients will be given tamoxifen with antioxidant. Then at the interval of 3 and 6 months after treatment , semen analysis and hormonal profile will be repeated. Pre-treatment and post treatment semen parameters will be compared using paired sample t-test. P-value < 0.05 will be taken as significant.

Read the detailed description

Infertility is considered as the most important issue among the married couples and it represents major clinical problems affecting people not just medically but also psychologically .

Infertility affects about 5-8% of couple in developed countries and 5.8 - 44.2% in developing nations. In Pakistan incidence of oligozoospermia is around 21 percent and 12.32 % of patients presents with azoospermia (2). Male infertility contributes to about 50% of the cases of infertility . Cause of male infertility with abnormal semen parameters remains unknown in about 25% of men Men with idiopathic infertility may receive number of empirical therapies by clinicians. Commonly prescribed medications include hormonal medications such as follicular stimulating hormone (FSH), androgens like testosterone and mesterolone, antiestrogens ( tamoxifine, clomiphene citrate) , antioxidents like vitamin E, glutathione and sperm vitalizer such as L-carnitine ,coQ10.

Antiestrogens are considered to be one of the oldest and most commonly prescribed treatment for the idiopathic male infertility. Antiestrogen given for 6-9 months reported to have pregnancy rate of 20-40% . According to WHO tamoxifen citerate is the first line treatment for idiopathic ologozoospermia . Previously tamoxifen citrate was given as the empirical treatment for oligozoospermia and later it was found that after the use of 3-6 months it improves sperm count, motility and viability . The exact mechanism by which tamoxifen increase sperm parameters is not known , however it is found that it has stimulatory action on gonadotrophin secretion and directly effects leydig cell function . Tamoxifen is also known for the treatment of breast cancer worldwide.

Oxidative stress has been widely studied previously as one of the cause of the male infertility. Like other aerobic cells , spermatozoa are also prone to the oxidative damage because they have large polyunsaturated fat content in their membrane. Men who have high reactive oxygen species(ROS) may have lower fertility potential as compared to men with low ROS. High levels of ROS in semen have been correlated with reduced sperm motility and damage to sperm nuclear DNA. High levels of cytokines in the semen is correlated with sperm injury like cell membrane lipid peroxidation in the presence of raised IL-6 . Interferone gamma and TNF alpha have shown to decrease the motility of spermatozoa. This is commonly present in genitourinary infections and inflammation in which oxidative mechanism can leads to oxidative stress . Antioxidents are the most important form of protection for spermatozoa against ROS. So oral antioxidents are commonly prescribed to males with idiopathic abnormal semen parameters and infertility to reduce the oxidative stress and improves infertility.

Though assisted reproductive techniques are being widely offered to infertile couples, however before referring the patients for these expensive treatment options , relatively economical and practical methods should be considered first.

This study has been designed to determine the improvement of semen quality of infertile male with abnormal parameters after treatment with tamoxifen \& tamoxifen with antioxidants thus the chances of conception and pregnancy rates are expected to be improved.

OBJECTIVE:

To compare the efficacy of tamoxifen alone \& tamoxifen with antioxidant on semen quality of infertile male with abnormal parameters (sperm count, motility, vitality, morphology) .

OPERATIONAL DEFINITIONS:

Infertility: Inability to conceive after one year of unprotected and regular intercourse.

Abnormal Semen parameters:

Oligospermia: A sperm count of less than 15 million/ml .

Azoospermia: Absence of spermatozoa in the semen. Asthenozoospermia: reduced sperm motility. Teratozoospermia: presence of spermatozoa with abnormal morphology Asthenoteratozoospermia: Abnormal sperm motility and morphology

MATERIALS AND METHODS:

Study Design: Single Blind Randomized Controlled Trial Setting: Department of Obstetrics and Gynecology, Sharif Medical City, Lahore for 1 years.

Sampling Technique: Probability Randomized Consecutive Sampling Technique.

SAMPLE SELECTION:

Sample Size: A sample size of 110 (55in each group) with 95% confidence interval at 5% level of significance.

DATA COLLECTION PROCEDURE:

After approval of proposed synopsis from the ethical review board, infertile males with abnormal semen parameters will be included in the study after written informed consent. Randomization will be done by lottery method to divide the patients into group A \& group B.

In group A: Tab. Tamoxifen 10 mg ,per oral twice daily will be given for six months.

In group B: Tab. Tamoxifen 10mg twice a day and Cap Evion 400mg once a day will be given for six months.

Semen analysis will be performed, according to the WHO criteria 20101, on all the patients for measurement of semen parameters ( volume, sperm concentration, total sperm number, motility \& morphology) All samples will be collected in a private room at the laboratory in Sharif medical city, wide-mouth container kept at body temperature, after abstaining from any sexual activity for no less than 3 and no more than 7 days. Masturbation will be used as the method of sample production, without the use of any lubricants, after washing and drying both the hands and the penis. The sample is then incubated at 37 ºC till liquefaction is complete.

Semen volume will be measured in a graduated cylinder, whereas, sperm count and morphology will be assessed by microscopy. Sperms appearing within a square on the grid pattern will be counted to determine the sperm count.

Hormonal profile such as Serum FSH, serum LH and Serum Testosterone of all patients will also be analyzed before starting the treatment. Semen samples and hormonal profile will be analyzed pre-treatment and at interval of three months and six months after treatment. All the research data will be taken on a pre-designed Performa.

DATA ANALYSIS:

Data analysis will be done using SPSS v 23. Quantitative variables such as age, sperm count, motility, and vitality concentration will be analyzed and mean and standard deviation will be calculated. Independent sample test will be used to compare quantitative variables between the groups. While pre-treatment and post treatment semen parameters will be compared using paired sample t-test. P-value < 0.05 will be taken as significant. Bias will be reduced by using the same laboratory for all tests. Data, will be stratified for age, BMI, smoking ,alcohol drinking, baseline sperm parameters (sperm count, concentration , motility, vitality) and hormone assays (follicular stimulating hormone (FSH), luteinizing hormone(LH) and testosterone).

Being tested
Tab Tamoxifen 10 mg, Tab Tamoxifen 10mg,Cap vitamin E 400mg
Keywords
Tamoxifen citerate, Anti oxidants
Medical subject headings
Oligospermia, Infertility, Male

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tab Tamoxifen 10 mgDrug

    Also called Group A

    Tablet tamoxifen 10mg twice a day for 6 months.

  • Tab Tamoxifen 10mg,Cap vitamin E 400mgDrug

    Also called Group B

    Tab tamoxifen 10 mg is given twice a day and cap vit E 400mg is given once a day for 6 months

Study groups in NCT05200663
Study groupRoleWhat they receive
"Tamoxifen"ExperimentalGroup A patients will receive tab tamoxifen 10 mg twice a day for total of six months.
Receives: Drug: Tab Tamoxifen 10 mg
"Tamoxifen and Antioxidant"Active comparatorGroup B patients will receive tab tamoxifen 10 mg twice a day and cap. vit E 400mg once a day for total of six months.
Receives: Drug: Tab Tamoxifen 10mg,Cap vitamin E 400mg

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Semen Volume

    Semen Volume measured in ml.

    Measured: at 3 months posttreatment

  2. Semen Volume

    Semen Volume measured in ml.

    Measured: at 6 months posttreatment

  3. Total sperm Count

    Total Sperm No.(x106)

    Measured: 3 months posttreatment

  4. Total sperm Count

    Total Sperm No.(x106):

    Measured: 6 months posttreatment

  5. Sperm concentration

    Sperm Conc. (x106)/ ejeculate:

    Measured: 3 months posttreatment

  6. Sperm concentration

    Sperm Conc. (x106)/ ejeculate:

    Measured: 6 months posttreatment

  7. Progressive motility

    Progressive motility in (Percentage %):

    Measured: 3 months posttreatment.

  8. Progressive motility

    Progressive motility (Percentage %):

    Measured: 6 months posttreatment

  9. Sperm Morphology:

    Sperm Morphology: Percentage %

    Measured: 3 months posttreatment

  10. Sperm Morphology:

    Sperm Morphology: Percentage %

    Measured: 6 months posttreatment

  11. Vitality

    Vitality (live spermatozoa in percentage%

    Measured: 3 months posttreatment

  12. Vitality

    Vitality (live spermatozoa) in percentage%

    Measured: 6 months posttreatment

  13. Leutinizing hormone

    Leutinizing hormone (LH) measured in mU/ml

    Measured: 3 months posttreatment

  14. Leutinizing hormone

    Leutinizing hormone (LH) measured in mU/ml

    Measured: 6 months posttreatment

  15. Follicular stimulating hormone

    Follicular stimulating hormone (LH) measured in mU/ml

    Follicular stimulating hormone (FSH) measured in mU/ml

    Measured: 3 months posttreatment.

  16. Follicular stimulating hormone

    Follicular stimulating hormone (LH) measured in mU/ml

    Follicular stimulating hormone (FSH) measured in mU/ml

    Measured: 6 months posttreatment.

  17. Serum Testosterone

    Serum Testosterone measured in ng/dl

    Measured: 3 months posttreatment.

  18. Serum Testosterone

    Serum Testosterone measured in ng/dl

    Measured: 6 months posttreatment.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jan 2022
  2. Study start15 Oct 2021
  3. Primary completionOct 2022 (estimated)
  4. Study completionOct 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
110 patients are recruited into two groups .55 patients in group A will be given tamoxifen 10 mg twice a day and 55 patients in group B will be given tamoxifen 10 mg twice a day and vit E 400mg once a day.
Masking
Single blind
Who is masked
Participant
Enrolment
110 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05200663
Sponsor's protocol ID
SMDC/SMRC/213-21/2021
Status last verified
Dec 2021
First submitted
24 Nov 2021
Last updated
21 Jan 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Meng Q, Ren A, Zhang L, Liu J, Li Z, Yang Y, Li R, Ma L. Incidence of infertility and risk factors of impaired fecundity among newly married couples in a Chinese population. Reprod Biomed Online. 2015 Jan;30(1):92-100. doi: 10.1016/j.rbmo.2014.10.002. Epub 2014 Oct 13.

    PubMed 25456165
  • Butt F, Akram N. Semen analysis parameters: experiences and insight into male infertility at a tertiary care hospital in Punjab. J Pak Med Assoc. 2013 May;63(5):558-62.

    PubMed 23757979
  • Safarinejad MR. The effect of coenzyme Q(1)(0) supplementation on partner pregnancy rate in infertile men with idiopathic oligoasthenoteratozoospermia: an open-label prospective study. Int Urol Nephrol. 2012 Jun;44(3):689-700. doi: 10.1007/s11255-011-0081-0. Epub 2011 Nov 13.

    PubMed 22081410
  • Siddiq FM, Sigman M. A new look at the medical management of infertility. Urol Clin North Am. 2002 Nov;29(4):949-63. doi: 10.1016/s0094-0143(02)00085-x.

    PubMed 12516764
  • 5. Iacono F, Prezioso D, Ruffo A et al. Treating idiopathic male infertility with a combination of tamoxifen citrate and a natural compost of antioxidant and androgen mimetic action. J Steroid Hormone Sci. 2013;S5: 1-6.

  • Kadioglu TC. Oral tamoxifen citrate treatment is more effective in normogonadotropic patients who have follicle-stimulating hormone levels within the lower half of normal. Int Urol Nephrol. 2009 Dec;41(4):773-6. doi: 10.1007/s11255-009-9568-3. Epub 2009 Apr 21.

    PubMed 19381855
  • Adamopoulos DA. Medical treatment of idiopathic oligozoospermia and male factor subfertility. Asian J Androl. 2000 Mar;2(1):25-32.

    PubMed 11228933
  • Nada EA, El Taieb MA, Ibrahim HM, Al Saied AE. Efficacy of tamoxifen and l-carnitine on sperm ultrastructure and seminal oxidative stress in patients with idiopathic oligoasthenoteratozoospermia. Andrologia. 2015 Sep;47(7):801-10. doi: 10.1111/and.12333. Epub 2014 Oct 2.

    PubMed 25274200
  • Sharma RK, Agarwal A. Role of reactive oxygen species in male infertility. Urology. 1996 Dec;48(6):835-50. doi: 10.1016/s0090-4295(96)00313-5.

    PubMed 8973665

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Tab Tamoxifen 10 mg and Tab Tamoxifen 10mg,Cap vitamin E 400mg in people with Oligoasthenoteratozoospermia and Male Infertility, run by Sharif Medical Research Center at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Jan 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Anees Fatima, MBBS,FCPS. (03456224197 ext. +92, fatima.tabjeel@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Semen Volume (time frame: at 3 months posttreatment). The study lists 18 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05200663, which also lists 9 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in